| 1 |
Bagley WH, Yang H, Shah KH. Rhabdomyolysis[J]. Intern Emerg Med, 2007, 2(3): 210-218.
|
| 2 |
Sauret JM, Marinides G, Wang GK. Rhabdomyolysis[J]. Am Fam Physician, 2002, 65(5): 907-912.
|
| 3 |
Holt SG, Moore KP. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis[J]. Intensive Care Med, 2001, 27(5): 803-811.
|
| 4 |
Alpers JP, Jones LK Jr. Natural history of exertional rhabdomyolysis: a population-based analysis[J]. Muscle Nerve, 2010, 42(4): 487-491.
|
| 5 |
Perreault S, Birca A, Piper D, et al. Transient creatine phosphokinase elevations in children: a single-center experience[J]. J Pediatr, 2011, 159(4): 682-685.
|
| 6 |
Mackay MT, Kornberg AJ, Shield LK, et al. Benign acute childhood myositis: laboratory and clinical features[J]. Neurology, 1999, 53(9): 2127-2131.
|
| 7 |
Zimmerman JL, Shen MC. Rhabdomyolysis[J]. Chest, 2013, 144(3): 1058-1065.
|
| 8 |
Wen X, Peng Z, Kellum JA. Pathogenesis of acute kidney injury: effects of remote tissue damage on the kidney[J]. Contrib Nephrol, 2011, 174: 129-137.
|
| 9 |
Belliere J, Casemayou A, Ducasse L, et al. Specific macrophage subtypes influence the progression of rhabdomyolysis-induced kidney injury[J]. J Am Soc Nephrol, 2015, 26(6): 1363-1377.
|
| 10 |
de Meijer AR, Fikkers BG, de Keijzer MH, et al. Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey[J]. Intensive Care Med, 2003, 29(7): 1121-1125.
|
| 11 |
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis[J]. Kidney Int, 2012, 81(5): 442-448.
|
| 12 |
Panizo N, Rubio-Navarro A, Amaro-Villalobos JM, et al. Molecular Mechanisms and Novel Therapeutic Approaches to Rhabdomyolysis-Induced Acute Kidney Injury[J]. Kidney Blood Press Res, 2015, 40(5): 520-532.
|
| 13 |
Brown CV, Rhee P, Chan L, et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? [J]. J Trauma, 2004, 56(6): 1191-1196.
|
| 14 |
Mulay SR, Kumar SV, Lech M, et al. How Kidney Cell Death Induces Renal Necroinflammation[J]. Semin Nephrol, 2016, 36(3): 162-173.
|
| 15 |
Moreno JA, Martín-Cleary C, Gutiérrez E, et al. AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences[J]. Clin J Am Soc Nephrol, 2012, 7(1): 175-184.
|
| 16 |
Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury[J]. Clin Immunol, 2009, 130(1): 41-50.
|
| 17 |
Gonzalez-Michaca L, Farrugia G, Croatt AJ, et al. Heme: a determinant of life and death in renal tubular epithelial cells[J]. Am J Physiol Renal Physiol, 2004, 286(2): F370-377.
|
| 18 |
Moreno JA, Martín-Cleary C, Gutiérrez E, et al. Haematuria: the forgotten CKD factor? [J]. Nephrol Dial Transplant, 2012, 27(1): 28-34.
|
| 19 |
Wagener FA, Feldman E, de Witte T, et al. Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells[J]. Proc Soc Exp Biol Med, 1997, 216(3): 456-463.
|
| 20 |
Komada T, Usui F, Kawashima A, et al. Role of NLRP3 Inflammasomes for Rhabdomyolysis-induced Acute Kidney Injury[J]. Sci Rep, 2015, 5: 10901.
|
| 21 |
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 2012, 149(5): 1060-1072.
|
| 22 |
Xie Y, Hou W, Song X, et al. Ferroptosis: process and function[J]. Cell Death Differ, 2016, 23(3): 369-379.
|
| 23 |
Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models[J]. J Am Chem Soc, 2014, 136(12): 4551-4556.
|
| 24 |
Chatzizisis YS, Misirli G, Hatzitolios AI, et al. The syndrome of rhabdomyolysis: complications and treatment[J]. Eur J Intern Med, 2008, 19(8): 568-574.
|
| 25 |
Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury[J]. N Engl J Med, 2009, 361(1): 62-72.
|
| 26 |
Zarjou A, Bolisetty S, Joseph R, et al. Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury[J]. J Clin Invest, 2013, 123(10): 4423-4434.
|
| 27 |
Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death[J]. Nat Chem Biol, 2014, 10(1): 9-17.
|
| 28 |
Fähling M, Mathia S, Paliege A, et al. Tubular von Hippel-Lindau knockout protects against rhabdomyolysis-induced AKI[J]. J Am Soc Nephrol, 2013, 24(11): 1806-1819.
|
| 29 |
Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels[J]. Nature, 2007, 447(7146): 864-868.
|
| 30 |
Sogabe K, Roeser NF, Venkatachalam MA, et al. Differential cytoprotection by glycine against oxidant damage to proximal tubule cells[J]. Kidney Int, 1996, 50(3): 845-854.
|
| 31 |
Gao M, Monian P, Quadri N, et al. Glutaminolysis and Transferrin Regulate Ferroptosis[J]. Mol Cell, 2015, 59(2): 298-308.
|
| 32 |
Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156(1-2): 317-331.
|
| 33 |
Gao M, Monian P, Jiang X. Metabolism and iron signaling in ferroptotic cell death[J]. Oncotarget, 2015, 6(34): 35145-35146.
|
| 34 |
Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 2015, 520(7545): 57-62.
|
| 35 |
Hayano M, Yang WS, Corn CK, et al. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation[J]. Cell Death Differ, 2016, 23(2): 270-278.
|
| 36 |
Herbison CE, Thorstensen K, Chua AC, et al. The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells[J]. Am J Physiol Cell Physiol, 2009, 297(6): C1567-C1575.
|
| 37 |
Sun X, Ou Z, Xie M, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death[J]. Oncogene, 2015, 34(45): 5617-5625.
|
| 38 |
Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63(1): 173-184.
|
| 39 |
Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J]. Nat Cell Biol, 2014, 16(12): 1180-1191.
|
| 40 |
Yang WS, Kim KJ, Gaschler MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis[J]. Proc Natl Acad Sci U S A, 2016, 113(34): E4966-E4975.
|
| 41 |
Conrad M, Friedmann Angeli JP. Glutathione peroxidase 4 (Gpx4) and ferroptosis: what's so special about it? [J]. 43 Mol Cell Oncol, 2015, 2(3): e995047.
|
| 42 |
Yuan H, Li X, Zhang X, et al. Identification of ACSL4 as a biomarker and contributor of ferroptosis[J]. Biochem Biophys Res Commun, 2016, 478(3): 1338-1343.
|
| 43 |
Hou W, Xie Y, Song X, et al. Autophagy promotes ferroptosis by degradation of ferritin[J]. Autophagy, 2016, 12(8): 1425-1428.
|
| 44 |
Bellelli R, Federico G, Matte' A, et al. NCOA4 Deficiency Impairs Systemic Iron Homeostasis[J]. Cell Rep, 2016, 14(3): 411-421.
|
| 45 |
Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death[J]. Nat Chem Biol, 2014, 10(1): 9-17.
|
| 46 |
Gao M, Monian P, Pan Q, et al. Ferroptosis is an autophagic cell death process[J]. Cell Res, 2016, 26(9): 1021-1032.
|
| 47 |
Ou Y, Wang SJ, Li D, et al. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses[J]. Proc Natl Acad Sci U S A, 2016, 13(44): E6806-E6812.
|
| 48 |
Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models[J]. J Am Chem Soc, 2014, 136(12): 4551-4556.
|
| 49 |
Garg JP, Vucic D. Targeting Cell Death Pathways for Therapeutic Intervention in Kidney Diseases[J]. Semin Nephrol, 2016, 36(3): 153-161.
|
| 50 |
Matsushita M, Freigang S, Schneider C, et al. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection[J]. J Exp Med, 2015, 212(4): 555-568.
|
| 51 |
Skouta R, Dixon SJ, Wang J, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models[J]. J Am Chem Soc, 2014, 136(12): 4551-4556.
|
| 52 |
Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis[J]. Proc Natl Acad Sci U S A, 2014, 111(47): 16836-16841.
|
| 53 |
Yang WS, Stockwell BR. Ferroptosis: Death by Lipid Peroxidation[J]. Trends Cell Biol, 2016 26(3): 165-176.
|
| 54 |
Paller MS. Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity[J]. Am J Physiol, 1988, 255(3 Pt 2): F539-F544.
|
| 55 |
Reeder BJ, Wilson MT. Desferrioxamine inhibits production of cytotoxic heme to protein cross-linked myoglobin: a mechanism to protect against oxidative stress without iron chelation[J]. Chem Res Toxicol, 2005, 18(6): 1004-1011.
|
| 56 |
Groebler LK, Liu J, Shanu A, et al. Comparing the potential renal protective activity of desferrioxamine B and the novel chelator desferrioxamine B-N-(3-hydroxyadamant-1-yl) carboxamide in a cell model of myoglobinuria[J]. Biochem J, 2011, 435(3): 669-677.
|
| 57 |
Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, et al. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)[J]. Transfus Sci, 2000, 23(3): 211-223.
|
| 58 |
Dixon SJ, Patel DN, Welsch M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis[J]. Elife, 2014, 3: e02523.
|
| 59 |
Wang AW, Song L, Miao J, et al. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice[J]. Am J Hypertens, 2015, 28(4): 518-526.
|
| 60 |
Chen HM, Liou SF, Hsu JH, et al. Baicalein inhibits HMGB1 release and MMP-2/-9 expression in lipopolysaccharide-induced cardiac hypertrophy[J]. Am J Chin Med, 2014, 42(4): 785-797.
|
| 61 |
Lai CC, Huang PH, Yang AH, et al. Baicalein, a Component of Scutellaria baicalensis, Attenuates Kidney Injury Induced by Myocardial Ischemiaand Reperfusion[J]. Planta Med, 2016, 82(3): 181-189.
|
| 62 |
Xie Y, Song X, Sun X, et al. Identification of baicalein as a ferroptosis inhibitor by natural product library screening[J]. Biochem Biophys Res Commun, 2016, 473(4): 775-780.
|
| 63 |
Albert C, Haase M, Bellomo R, et al. High cut-off and high-flux membrane haemodialysis in a patient with rhabdomyolysis-associated acute kidney injury[J]. Crit Care Resusc, 2012, 14(2): 159-162.
|
| 64 |
Heyne N, Guthoff M, Krieger J, et al. High cut-off renal replacement therapy for removal of myoglobin in severe rhabdomyolysis and acute kidney injury: a case series[J]. Nephron Clin Pract, 2012, 121(3-4): c159-c164.
|